IR@PKUHSC  > 北京大学第二临床医学院  > 血液科
学科主题临床医学
Rituximab After Autologous Stem Cell Transplantation Enhances Survival of B-cell Lymphoma Patients: A Meta-Analysis and Systematic Review
He, G.1,2; Wang, C.1; Tan, H.1; He, S.3
刊名TRANSPLANTATION PROCEEDINGS
2015-03-01
DOI10.1016/j.transproceed.2014.11.040
47期:2页:517-522
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Immunology ; Surgery ; Transplantation
研究领域[WOS]Immunology ; Surgery ; Transplantation
关键词[WOS]NON-HODGKINS-LYMPHOMA ; BONE-MARROW-TRANSPLANTATION ; SALVAGE CHEMOTHERAPY ; AGGRESSIVE LYMPHOMA ; THERAPY ; DISEASE
英文摘要

Background. Numerous studies have demonstrated the efficacy of rittudmab before autologous stem cell transplantation (ASCT) for the treatment of B-cell non-Hodgkin lymphoma, but the few studies on rituximab treatment after ASCT have not established conclusively the clinical benefits of this particular treatment regimen.

Patients and Methods. We conducted a metaanalysis of 3 comparative studies encompassing 407 lymphoma patients treated with rituximab after ASCT.

Results. Combined results revealed a significantly higher event-free survival (EFS) in the rituximab-treated (R+) group compared with the R group (P = .003 at 1 year; P = .03 at 3 years; P = .001 at 4 years). Moreover, the R+ group also demonstrated higher overall survival (OS) and complete remission (CR) rates (P = .0006 and P < .0001, respectively, at 1 year) without a significant increase in adverse events.

Conclusions. According to the included articles, there were no differences in CR, overall response, 3-year EFS, or 3-year OS between rituximab-naive patients and patients previously treated with rituximab before AS CT. Post-AS CT maintenance regimens including rittudmab show increased EFS, OS, and CR.

语种英语
WOS记录号WOS:000351480600047
引用统计
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/62568
专题北京大学第二临床医学院_血液科
作者单位1.Peking Univ, Inst Hematol, Peoples Hosp, Beijing 100871, Peoples R China
2.Guangzhou Med Univ, Affiliated Hosp 1, Ctr Oncol & Hematol, Guangzhou 510000, Guangdong, Peoples R China
3.Sun Yat Sen Univ, Sch Publ Hlth, Guangzhou 510275, Guangdong, Peoples R China
推荐引用方式
GB/T 7714
He, G.,Wang, C.,Tan, H.,et al. Rituximab After Autologous Stem Cell Transplantation Enhances Survival of B-cell Lymphoma Patients: A Meta-Analysis and Systematic Review[J]. TRANSPLANTATION PROCEEDINGS,2015,47(2):517-522.
APA He, G.,Wang, C.,Tan, H.,&He, S..(2015).Rituximab After Autologous Stem Cell Transplantation Enhances Survival of B-cell Lymphoma Patients: A Meta-Analysis and Systematic Review.TRANSPLANTATION PROCEEDINGS,47(2),517-522.
MLA He, G.,et al."Rituximab After Autologous Stem Cell Transplantation Enhances Survival of B-cell Lymphoma Patients: A Meta-Analysis and Systematic Review".TRANSPLANTATION PROCEEDINGS 47.2(2015):517-522.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[He, G.]的文章
[Wang, C.]的文章
[Tan, H.]的文章
百度学术
百度学术中相似的文章
[He, G.]的文章
[Wang, C.]的文章
[Tan, H.]的文章
必应学术
必应学术中相似的文章
[He, G.]的文章
[Wang, C.]的文章
[Tan, H.]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。